Scientific deep-dive

Melanotan and the Approved Drug It Is Not

An approved melanocortin-1 receptor agonist exists — afamelanotide, for preventing phototoxic pain in erythropoietic protoporphyria, given as a 16 mg implant under supervision. Melanotan sold for cosmetic tanning is not that drug.

By Ruth Calder · Enforcement Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
5 min read·1 citations

There is an approved melanocortin‑1 receptor agonist. It is called afamelanotide, it went through phase 3 trials, and it is approved in the EU for one thing: preventing phototoxicity in adults with erythropoietic protoporphyria, a rare disorder in which sunlight causes pain. It is given as a biodegradable controlled-release implant containing 16 mg, under medical supervision.[1] Melanotan sold online for cosmetic tanning is not that drug, and the difference is the whole point.

What the approved one is for

Erythropoietic protoporphyria is a genetic condition in which exposure to light causes burning pain. In the phase 3 trial CUV039, afamelanotide improved light tolerance: patients spent more time in direct sunlight without pain, and it took longer for the first symptoms of phototoxicity to appear under a standardized light source. It was generally well tolerated, with no drug-related serious adverse events reported; common reactions were headache and implant-site reactions.[1]

Read what that indication actually is. The drug is approved to let people with a painful genetic photosensitivity disorder go outside. It is not approved to make anyone browner, and the trials measured pain-free time in sunlight, not appearance.

The four differences that matter

Why the existence of an approved analog says little about an unapproved one.
AfamelanotideMelanotan sold online
Regulatory statusApproved (EU) for a named conditionUnapproved research chemical
PurposePreventing phototoxic pain in EPPCosmetic tanning
Form and dose16 mg controlled-release implantSelf-injected, dose set by the buyer
OversightPrescribed and administered clinicallyNone
A controlled-release implant placed by a clinician delivers a known quantity over a known period. A vial of powder reconstituted at home and injected to effect does not. Even if the molecules were identical — and they are not — those are different exposures, and dose is most of what determines whether a drug is a medicine or a problem.

What we are not claiming, and why

Melanotan is frequently discussed in connection with changing moles and with melanoma. There is published case-report literature on that association. We looked at the most-cited example and its record carries no abstract we could read — a title and errata only. Rather than cite a paper we could not read and let you assume we had checked its contents, we are telling you the position: we did not verify those case details, so we are not building a claim on them.

What can be said without that literature is enough to act on. A compound that stimulates melanocytes, taken at an unmeasured dose, without supervision, for a cosmetic purpose, by people who are by definition seeking more pigment change than their skin produces on its own, is not a situation in which anyone is monitoring their moles. That is a reason for caution regardless of what any individual case report says.

  • Melanotan is not approved anywhere for cosmetic tanning.
  • Products sold under the name are research chemicals with no identity, purity or dose guarantee.
  • The existence of an approved melanocortin agonist for a rare photosensitivity disorder is not evidence for an unapproved analog used cosmetically.
  • ⚠ Any new, changing or asymmetric mole is worth showing to a doctor, and more so if you are using something that acts on melanocytes.

For the regulatory position on research-use peptides generally, see what FDA actually said about BPC-157. The peptides this register profiles in full are at /peptides.

Frequently Asked Questions

Not for cosmetic tanning, anywhere. A related melanocortin-1 receptor agonist, afamelanotide, is approved in the EU for preventing phototoxicity in adults with erythropoietic protoporphyria — a rare genetic photosensitivity disorder — as a 16 mg controlled-release implant.
No. It is a different compound, for a different purpose, delivered as a clinician-placed implant at a controlled dose, under supervision. Melanotan sold online is self-injected at a dose the buyer chooses. Those are different exposures even setting the molecules aside.
There is published case-report literature discussing that association. We could not retrieve the text of the most-cited example, so we are not making a claim about what those cases showed. Separately, anything that acts on melanocytes is a reason to have moles checked rather than assume.
Time spent in direct sunlight without pain, and time to the first symptoms of phototoxicity under a standardized light source, in patients with erythropoietic protoporphyria. It did not measure tanning or appearance.

References

  1. 1.Kim ES, Garnock-Jones KP. Afamelanotide: A Review in Erythropoietic Protoporphyria American Journal of Clinical Dermatology. 2016. PMID: 26979527.

DSIP: A Sleep Peptide Named in 1977, With No Known Receptor

Delta sleep-inducing peptide was isolated in 1977 and named for what researchers hoped it did. A review of the field states the sleep hypothesis is extremely poorly documented and weak, and that no gene, protein or receptor has been isolated.

4 min read

Elamipretide (SS-31): The Phase 3 Trial That Missed Both Endpoints

Elamipretide has what almost no research-use peptide has — a completed pivotal phase 3 trial in 218 people. It missed both primary endpoints, with a six-minute walk difference of -3.2 meters and a p value of 0.69.

5 min read

LL-37: Thousands of Papers, No Human Trials

LL-37 is the body's own cathelicidin and the subject of thousands of papers. Read what they are and it is structural biology, cell culture and mice — including a wound-healing study in diabetic mice. We found no human clinical trial.

5 min read

MK-677: A Real Trial in Eight People, and a Liver Report

A 1998 randomized crossover trial found MK-677 reversed diet-induced protein catabolism, moving nitrogen balance from -2.67 to +0.31 g/day. It enrolled eight people and measured a proxy. A 2025 case report describes liver injury after two months of use.

5 min read

NAD+ Injections: What the Evidence Shows

A 2026 systematic review screened 113 studies and found no outcomes trials of injected NAD+ for anti-aging or wellness. It is the most common add-on in our 560-seller register, offered by 142 of them.

7 min read

Selank: Real Clinical Trials, One Country, No Replication

Selank was tested against a benzodiazepine in 62 patients with generalized anxiety disorder and reported similar anxiolytic effects. The study is from 2008, published in Russian, and has never been independently replicated.

5 min read

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

5.7

HumeCare+

An oral route if you will not self-inject

9.0

Care Bare Rx

Knowing which pharmacy fills the vial — it names Belmar Pharmacy

8.4

Enhance MD

Knowing which pharmacy fills the vial — it names Tru Meds Rx